Finally, Maviret, AbbVie’s hepatitis C drug, has made it through Canada’s approval process and has been listed for coverage by Ontario’s PharmaCare. We hope BC PharmaCare will also list it soon.

  • “MAVIRET is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment (from: Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016 and 2017)
  • MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease”

https://www.newswire.ca/news-releases/abbvie-reaches-an-agreement-with-the-pan-canadian-pharmaceutical-alliance-pcpa-for-its-hepatitis-c-treatment-maviret-tm–822598355.html

See HepCBC’s patient-group recommendations about Maviret to CADTH and BC PharmaCare in 2017:

MAVIRET™ (CNW Group/AbbVie)